MÉRIEUX-EQUITY
18.2.2021 08:02:12 CET | Business Wire | Press release
AcuSurgical, a Montpellier-based company focused on robotic microsurgery, today announces a €5.75 million Series A financing round led by Mérieux Equity Partners (via OMX Europe Venture Fund) and Supernova Invest (via Supernova 2 Fund), with Sofimac Innovation (via Pertinence Invest 2 Fund) and IRDI Capital Investissement (via Irdinov 2 and Inn’Vest PME Occitanie Est Funds) participating in the round.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210217005035/en/
Using advanced robotics, AcuSurgical is making ocular microsurgery safer and more accessible by dramatically improving the precision of surgical interventions. A proof of concept of the platform has already been completed with a first prototype validated in a preclinical setting.
The company will use the proceeds of the Series A financing to conduct clinical trials and reach regulatory approval with vitreo-retinal surgery as the first indication, paving the way for future applications that are not within the reach of surgeons today.
Retinal surgeries represent an annual global market of 1.6 million procedures, currently performed by a limited number of specialized surgeons. AcuSurgical’s robotic platform aims to increase the precision of current procedures, filtering tremor and augmenting visualization with the aid of a telemanipulated robot, while the surgeon remains in complete control.
Founded by Christoph Spuhler, serving as Chief Executive Officer, AcuSurgical has already attracted an experienced and highly skilled multidisciplinary team of executives, alongside the scientific co-founders, Prof. Yassine Haddab and Prof. Philippe Poignet, robotics experts at the joint research Unit LIRMM (Laboratory of Computer Science, Robotics and Microelectronics in Montpellier) and Prof. Philippe Gain and Prof. Gilles Thuret, retinal surgeons at the Saint-Etienne University Hospital.
“Our ambition is to enable new treatments for retinal disease that will open new perspectives for the numerous patients who are impacted by these debilitating retinal conditions. We are proud of the vote of confidence by this strong syndicate of investors. This financing will allow us to grow the team and reach key milestones towards certification and commercialisation of a truly innovative surgical solution”, s ays Christoph Spuhler, CEO and co-founder of AcuSurgical.
“We are delighted to partner with such an experienced team and look forward to supporting AcuSurgical in bringing to market a novel solution that will improve ocular surgeries and open new procedures in ophthalmology” , says Valérie Calenda, Managing Partner at Mérieux Equity Partners.
”The robotics platform developed by AcuSurgical aims to help retinal surgeons perform complex procedures more safely and reproducibly. We are very pleased to support this new venture and excellent team” says Celia Hart, General Partner at Supernova Invest.
About AcuSurgical - www.acusurgical.com
Founded in 2020, AcuSurgical is a surgical robotics company based in Montpellier (France). AcuSurgical's mission is to enable top-class treatment to the 300+ million patients suffering from retinal disease worldwide, a debilitating condition including age-related macular degeneration (AMD), diabetic retinopathy and macular holes. Worldwide, currently 1.6 million retinal surgeries are performed each year, with a yearly growth rate of 7%. This currently represents only a small percentage of actual cases, with the majority of patients, especially in emerging economies, getting inadequate treatment or often no treatment at all. The cutting-edge robotics platform from AcuSurgical aims to change this, bringing a new surgical paradigm to vitreo-retinal surgery based on precision robotics.
About Mérieux Equity Partners - www.merieux-partners.com
Mérieux Equity Partners (“MxEP”) is an investment company dedicated to capital investment in health and nutrition and registered with the Autorité des Marchés Financiers (AMF). MxEP actively supports entrepreneurs and companies with differentiated products and services, giving them privileged access to its sector expertise and international network. MxEP currently manages around €670 million of assets and launched their latest venture capital fund in 2020, OMX Venture Fund, to finance high potential companies in the life science space, in Europe and North America.
About Supernova Invest - www.supernovainvest.com
Supernova Invest is a cutting-edge venture capital firm with a leading position in the French deeptech investment market. It manages and advises five capital funds for a total of €260 million AUM. Supernova Invest specializes in breakthrough technologies, developing start-ups in Industry, Health, Energy & Environment and Digital Technology sectors. Supernova Invest has a strong partnership with both the CEA (the French Alternative Energies and Atomic Energy Commission) and Amundi (the European leader in asset management).
The FPCI Supernova 2 is an early-stage investment fund managed by Supernova Invest. Its main investors are the Crédit Agricole, the Fond National d’Amorçage managed by Bpi France, the CEA, Michelin, BioMérieux, Vinci, EDF, CGG, UDIMEC as well as entrepreneurs and family offices.
About Sofimac Innovation - www.sofimacinnovation.com
Sofimac Innovation is an independent management company certified by the financial markets regulator (AMF) and dedicated to technological and innovative investment. Based in Paris, Lyon, Rennes and Marseille, Sofimac Innovation supports innovative start-up in their growth projects with a wide range of investment vehicles. Working in a wide variety of technological sectors, particularly in Health and Digital sectors, Sofimac Innovation is currently managing 9 Funds comprising around 90 active companies.
Pertinence Invest 2 is an investment Fund managed by Sofimac Innovation, raised in partnership with prestigious Universities and Schools and renowned industrial corporates. Pertinence Invest 2 is investing in breakthrough technologies in the Engineering Sciences and Health & Nutrition sectors.
About IRDI Capital Investissement - www.irdi.fr
Based in Toulouse, Montpellier, and Bordeaux, IRDI Capital Investissement has been a key player in private equity for more than 35 years, with an investment track record in companies located in the South-West of France and at all development stages. It manages more than €350 million spread across several funds, including IRDINOV 2 and INN’VEST PME OCCITANIE EST which were both leveraged to invest in AcuSurgical.
IRDINOV 2 - supported by the Fonds National d’Amorçage (FNA) - is a capital seed fund specialized in financing technological companies.
INN’VEST PME OCCITANIE EST is a co-investment fund supported by the European Investment Fund (EIF) and the Région Occitanie under the FOSTER TPE PME fund of funds.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210217005035/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Summer Program from Corona Invites the World to Experience “This Is Living”11.5.2026 10:00:00 CEST | Press release
The brand moves from inspiration to action with “Living Is Calling,” a campaign to enjoy the outdoors through a global partnership with Tripadvisor Today, Corona, the world’s most valuable beer brand*, unveils “Living is Calling” – a new global call to action inviting consumers to step outside and live life to the fullest this summer. As a powerful extension of its “This Is Living” platform, the new campaign invites the world to put living first through a partnership with Tripadvisor featuring over 300,000 experiences, and a new global film. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260511429135/en/ “For the past 100 years, Corona has inspired the world to come outside and feel more moments of ‘This Is Living,’ and we believe the next chapter is about helping people take action and embrace the outdoors,” said Clarissa Pantoja, Global Vice President of Corona. “‘Living is Calling’ is our worldwide call to action, and we’
Braskem Celebrates Naming of Beautiful Future and Blooming Future, Next‑Generation Tankers for Cleaner Global Trade11.5.2026 10:00:00 CEST | Press release
Beautiful Future and Blooming Future combine cutting‑edge efficiency and emissions‑reduction technologies to support more responsible global trade. Braskem (B3: BRKM3, BRKM5, and BRKM6; NYSE: BAK; LATIBEX: XBRK), the largest polyolefins producer in the Americas and global leader in the production of biopolymers on an industrial scale announces today that Braskem Trading & Shipping (BT&S) has reached a major milestone in its fleet modernization and sustainability journey with the naming of Beautiful Future and Blooming Future, next‑generation chemical and product oil tankers designed to move essential raw materials more efficiently and with a significantly lower environmental footprint. Both vessels were formally named at a ceremony in China on May 8. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260511112306/en/ Beautiful Future Beautiful Future and Blooming Future are LR1 (Long Range 1) vessels that will transport naphtha,
Kiabi Selects Navan to Centralise Global Travel Program11.5.2026 09:00:00 CEST | Press release
Fashion retailer targets high employee adoption and efficiency with AI-powered travel platform Navan (NASDAQ: NAVN), the global AI-powered business travel and expense platform, today announced it has been selected by Kiabi, the French multinational fashion retailer, to consolidate its global travel with one unified platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260511547434/en/ Fashion retailer targets high employee adoption and efficiency with AI-powered travel platform To support its workforce of nearly 10,000 “Kiabers,” the retailer required a solution capable of providing an easy-to-use travel platform. Navan was selected due to its intuitive AI-powered interface and ability to integrate with Kiabi’s travel policies directly in-app. “Managing travel was becoming an administrative burden that slowed our teams down,” said Denise Maurice, Indirect Procurement Director at Kiabi. “We wanted to give our ‘Kiabers’ the
Owl Labs partners with Westcoast to expand access to seamless hybrid meeting experiences in the UK and Ireland11.5.2026 09:00:00 CEST | Press release
Partnership aims to reduce the ‘meeting tax’ by expanding access to Owl Labs products through Westcoast’s extensive distribution network Owl Labs, a global leader in AI-powered, 360-degree video conferencing solutions, today announced a new UK and Ireland distribution partnership with Westcoast Limited, one of the country’s largest and most trusted IT distributors. The agreement will see Westcoast distribute the full range of Owl Labs’ award-winning Meeting Owl and Owl Bar products across the UK and Ireland, providing greater choice, availability, and dedicated support for resellers and end customers navigating the demands of hybrid work. The partnership aims to address the technical setup challenges that plague meetings across the UK. Owl Labs’ recent State of Hybrid Work report found that nearly 8 in 10 workers (79%) lose time in meetings due to technical difficulties such as connecting to a meeting or setting up a camera. By making Owl Labs’ solutions simpler to source, deploy and s
Fujirebio Announces CE Marking of the Fully Automated Lumipulse® G pTau 217 Plasma Assay11.5.2026 09:00:00 CEST | Press release
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Fujirebio Europe N.V. has obtained a CE certificate of the Lumipulse G pTau 217 Plasma assay under the Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR). This CLEIA (chemiluminescent enzyme immunoassay) test allows for the quantitative measurement of Tau phosphorylated at threonine 217 (pTau 217) in human plasma (K2EDTA). “With Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma now CE‑marked on our LUMIPULSE G platform, we are advancing a new era of neurology diagnostics—one where blood‑based biomarkers enable earlier, broader, and more accessible insights into Alzheimer’s disease and neurodegeneration.” said Christiaan De Wilde, CEO at Fujirebio Europe N.V. “By delivering fully automated and scalable solutions, we are helping clinicians move decisively toward more timely and informed decision‑making. This milestone underscores our long‑term vision to reimagine the diagnostic
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom